NOS1 and lung cancer: Consistent with previous reports of a pro-tumorigenic role of NOS in lung cancer [6–9], we demonstrate that in a genetically engineered mouse model of Kras-driven NSCLC, L-NAME treatment inhibits lung tumor growth, reduces tumor burden, increases median OS, and improves HR, even when treatment is initiated in the presence of established disease.